Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 182 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neurofibromatosis Type 1 Clear all

Conditions: Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
Interventions: bevacizumab; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 2 more

Conditions: Neurofibromatosis Type 1
Interventions: Lovastatin ™, placebo; Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 8 Years to 15 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
Interventions: Not listed
Lead sponsor: House Ear Institute; Other
Eligibility: 5 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neurofibromas, Cutaneous, Neurofibromatosis 1
Interventions: Kybella; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MPNST, NF1, Sarcoma
Interventions: Selumetinib + ZEN-3694 ± Durvalumab; Combination Product
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma, Refractory Neurofibromatosis Type 1, Refractory Visual Pathway Glioma
Interventions: Biospecimen Collection, Selumetinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more

Conditions: Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor
Interventions: lapatinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Neurofibromatosis Type 1
Interventions: Frameshift Array blood sample test; Genetic
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Day to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas

Conditions: Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
Interventions: Laboratory Biomarker Analysis, Selumetinib Sulfate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Birmingham, Alabama • Bethesda, Maryland

Conditions: Neurofibromatosis 1
Interventions: NF1 Educational Videos, Peer Navigator, Letters about NF1 Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurofibromatosis 1, Social Skills
Interventions: PEERS; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 12 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions: tipifarnib, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
Interventions: GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
Interventions: Not listed
Lead sponsor: The Children's Tumor Foundation; Other
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2050
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: SkylineDx; Industry
Eligibility: 18 Years and older
Enrollment: 1,820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 9
States / cities: Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Interventions: Selumetinib, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more

Conditions: NEUROFIBROMATOSIS 1
Interventions: aminolevulinic acid; Drug
Lead sponsor: Donald Basel; Other
Eligibility: 14 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Neurofibromatosis Type 1, Tibial Dysplasia
Interventions: Not listed
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: Not listed
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions: Sunitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more

Conditions: Neurofibromatosis 1
Interventions: Abemaciclib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1)
Interventions: PAS-004 Tablets, PAS-004 Capsule; Drug
Lead sponsor: Pasithea Therapeutics Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Interventions: PD-0325901; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Neurofibromatosis Type 1
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Enrollment: 2,391 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

NF2 Natural History Consortium

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Frameshift Peptides of Children With NF1

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

The NF Registry Sponsored by the Children's Tumor Foundation

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

MElanoma Research Lymph Node Prediction Implementation National_001

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

Neurofibromatosis Type 1 Patient Registry